Evaluation of the Pharmacokinetics of Ulimorelin in Subjects With Hepatic Impairment and Healthy Subjects
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
Evaluation of the effect of hepatic impairment on the pharmacokinetics of ulimorelin after a
single intravenous (IV) dose in order to identify potential patients at risks in terms of
severity of hepatic dysfunction and to determine whether their dosage should be adjusted.